Feed ADXN
AD

Addex Therapeutics Ltd

ADXN · NASDAQ

$3.65 -5.44% (-$0.21)
1M -6.89%
Market Cap CHF 3.73M
P/E Ratio -
Div. Yield -
ROE 131.30%
Analiză

Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.

Piotroski F-Score Weak
1/9
Valuation
50 /100
Fair
P/S 50.39x
P/B 1.14x
P/E N/A
Growth
4 /100
Declining
Rev. growth 72.38%
Book val. growth 1.00%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 265.47%
Net margin 9,410.20%
Op. margin 3,630.79%
Quality
0 /100
Poor
ROIC 74.38%
ROE 131.30%
ROA 146.39%
Debt
54 /100
Moderate
Debt/Equity 0.03x
Current ratio 0.97x
Int. coverage -1,432.34x
Stability
1 /100
Unstable
Beta 1.96x
Rev. volatility 56.78%
EPS volatility 173.14%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre ADXN
Online

Despre companie

Addex Therapeutics Ltd (ADXN) is a Swiss biotechnology company focused on developing innovative drugs for the treatment of neurological and psychiatric disorders. The company leverages advanced technologies targeting allosteric modulation of receptors, enabling it to develop new therapeutic approaches for various conditions such as Parkinson's disease, schizophrenia, and other neurological disorders. Addex Therapeutics is known for its scientific expertise and strong focus on research and development. Addex Therapeutics Ltd (ADXN) shares could be suitable for investors looking for investments in the biotechnology and pharmaceutical research sector with an emphasis on innovative treatment methods.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Timothy Mark Dyer

Employees

3

Headquarters

Geneva

Evenimente viitoare

09 NOV.

Earnings

Upcoming earnings report

42d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.